Introduction
The bombesin family of peptides received their unusual name because bombesin and most of the subsequent other invertebrate members of this family were originally isolated from frog skins and they were named after the genus of the frog [1,2,3 ] they were isolated from (i.e. bombesin, the European frog Bombina bombina). Bombesin is a tetradecapeptide with a COOH terminus ending in Gly-His-Leu-Met-NH 2 , and subsequently was shown to closely resemble two mammalian bombesin-related peptides, gastrin-releasing peptide (GRP) and neuromedin B (NMB). GRP is a 27 amino acid peptide originally isolated from porcine stomach, which shares the same seven COOH terminal amino acids with bombesin, accounting for their similar biological activities. NMB is a decapeptide isolated from porcine spinal cord, which is similar to the frog peptide ranatensin, having a COOH terminus ending in Gly-His-Phe-Met-NH 2 [1, 2, 3 ]. The human GRP-encoding gene is on chromosome 18q21, and the NMB gene on chromosome 15q11 and they encode for 148 and 117 amino acid precursors, respectively. Studies of GRP and NMB immunoreactivity, as well as their mRNA, demonstrate that these peptides are widely distributed in mammals in the central nervous system (CNS) and peripheral tissues, especially in the gastrointestinal tract. In the gastrointestinal tract, GRP is found primarily in neurons, as well as submucosal and myenteric plexi, with the highest amounts in the colon and small intestine. NMB is found throughout the gastrointestinal tract, but in generally lower amounts than GRP. In the central nervous system, GRP is widely distributed in neurons, with high levels in the forebrain and hypothalamic nuclei, as well as in sensory nuclei, whereas NMB is most abundant in the olfactory bulb, dentate gyrus and dorsal root ganglia [3 ] .
Mammalian bombesin receptors
Three classes of closely related receptors constitute the mammalian bombesin family of receptors: a 384 amino acid GRP-preferring receptor (called GRPR or BB 2 -receptor), a 390-amino acid NMB-preferring receptor (NMBR or BB 1 -receptor), and a 399-amino acid orphan receptor termed bombesin-receptor-subtype-3 (called BRS-3 receptor or BB 3 -receptor), which has 47-52% homology with the GRPR and NMBR [3 ] . The natural ligand of the BRS-3 receptor is unknown and does not appear to be closely related to any known bombesinrelated peptide because this receptor in all species characterized (human, guinea pig, rat, sheep, mouse) has low affinity for all natural bombesin-related peptides [3 ,4] . Each of these receptors is a G protein-coupled receptor, which signal primarily through phospholipase C-mediated cascades, but also stimulate tyrosine phosphorylation of a number of signaling proteins, although in most tissues they do not activate adenylate cyclase [3 ] . The human BB 1 -receptor gene is at chromosome 6p21-pter; the BB 2 -receptor gene is at Xp22, and the human BB 3 -receptor gene is at Xq25 [3 ] .
Expression levels of these receptors have been studied in numerous species [3 ] , and in one detailed study in monkeys [5] , the highest levels of the BB 1 -receptor were in the testis and stomach, as well as in the central nervous system, including the amygdala, caudate nucleus, hippocampus, hypothalamus, thalamus, brain stem and spinal cord. In monkeys [5] , the highest levels of the BB 2 -receptor are in the pancreas, with lesser amounts in the prostate, stomach and skeletal muscle. In the monkey central nervous system, the BB 2 -receptor is widely distributed, with the highest amounts in the hypothalamus, basal ganglia and lateral olfactory tract nucleus. In the monkey [3 ], the BB 3 -receptor is found in the greatest amount in the testis and central nervous system, with the distribution more restricted than the BB 2 -receptor, but with high amounts of the BB 3 -receptor in the hypothalamus, followed by the pituitary gland, amygdala, hippocampus and caudate nucleus. In the rat gastrointestinal tract, using specific BB 3 -receptor antibodies [6], the BB 3 -receptor was detected in myenteric and submucosal ganglia and in the interstitial cells of Cajal, which led the authors to propose that it may play an important role in gastrointestinal motility.
The BB 1 -receptor has greater than a 100-fold higher affinity for NMB than GRP, whereas the BB 2 -receptor has a greater than 50-fold higher affinity for GRP than NMB [3 ] . Bombesin has relatively high affinity for both the BB 1 -receptor and the BB 2 -receptor and, therefore, many of the older pharmacological studies, both in vitro and in vivo, which usually used bombesin as the agonist, provide limited information about the subtype of bombesin receptor involved [3 ] . Whereas the BB 3 -receptor has a low affinity for all natural-occurring bombesinrelated peptides, a synthetic bombesin ligand, [D-Tyr 6 , b-Ala 11 , Phe 13 , Nle 14 ] bombesin 6-14 , has been described [7] , which has high affinity for the human and monkey BB 3 -receptor, and this peptide or its analogues are being widely used to study the presence of the BB 3 -receptor, as well as other bombesin receptors in human tissues by autoradiographic methods [8, 9, 10 ]. This synthetic peptide has the unique property of having high affinity also for the BB 1 -receptor and BB 2 -receptor from all species. Recently, however, using detailed structure-function studies of this ligand, a few selective BB 3 -receptor agonists have been described that may prove useful to study its role in physiology and disease processes [11] [12] [13] . A number of classes of high-affinity receptor antagonists are described for the BB 2 -receptor, but only a few with lower affinity exist for the BB 1 -receptor and none for the BB 3 -receptor, which could be useful to explore their roles in normal and pathologic conditions [3 ] . Due to the lack of good antagonists for all classes of these receptors, mice with targeted deletion of one of these receptors are being increasingly used to assess their roles in physiological and pathologic states.
Both GRP and NMB contain a COOH terminal amide that is essential for high-affinity interaction [3 ] . Recently, however, a number of studies have provided evidence that nonamidated precursor forms of GRP stimulate proliferation and migration of human colorectal cancer cells [14] [15] [16] through a novel receptor, which is at present uncategorized.
Bombesin peptides and their receptors: recent advances
In the following sections, specific advances with the GRP/ BB 2 -receptor, NMB/BB 1 -receptor and BB 3 -receptor are covered separately, except in the areas of satiety, antitumor treatment and imaging, which are considered together.
Gastrin-releasing peptide/BB 2 -receptors: recent advances GRP and stimulation of BB 2 -receptors are known to cause a broad spectrum of pharmacological and biological responses [3 ] . These responses include stimulation of smooth-muscle contraction in the gastrointestinal/ urogenital tract with profound effects on motility and gastrointestinal peristalsis [3 ,17] , potent effects on immune cells, stimulation of secretion and hormone release including insulin (gastric, pancreatic, colon, endocrine organs), potent growth effects on normal and neoplastic tissues [18 ,19 ] , and potent CNS effects including regulating circadian rhythm [20, 21] , thermoregulation, anxiety [22 ] , satiety [3 ] and various behavioral features [22 ] . Recent advances in the effect of GRP in cancer and satiety are discussed in a later section.
Recent studies suggest an important role for the GRP/ BB 2 -receptor in a number of new areas, including mediation of pruritus [23 ] , lung development and lung diseases [3 ,24,25,26 ,27] , small intestinal mucosal defense/prevention of injury [28] , and various CNS processes including memory. In a recent study [23 ] , evidence was presented that activation of the BB 2 -receptor in the dorsal spinal cord is important for mediating pruritus. GRPR knockout mice showed significantly decreased scratching behavior in response to pruritogenic stimuli, while other responses were normal. Furthermore, administration of a BB 2 -receptor antagonist into the spinal fluid inhibited scratching behavior in three different models of itching [23 ] . The authors [23 ] point out that the BB 2 -receptor may represent the first molecule identified that is dedicated to mediating the itch response in the spinal cord, and may provide an important therapeutic target for the treatment of chronic pruritic conditions. GRP/BB 2 -receptor activation is proposed to be important in normal lung development and in mediating the lung injury in premature infants with bronchopulmonary dysplasia (BPD) [3 ,24,25,26 ,27] . In one recent study [27] , GRP given to newborn mice induced features of human BPD, including interstitial pulmonary fibrosis and alveolarization. In a hyperoxic baboon model of BPD [26 ] , the early overproduction of bombesin-like peptides correlated with the development of BPD-like histologic features, and the blockage of GRP partially reversed these effects, leading the authors to suggest such an approach could have important implications for preventing BPD in premature infants. GRP has been shown to be protective to the small intestine in various injury models, enhance gut-barrier function, prevent the atrophy of enteric ganglia caused by FK506 in small bowel [29] [30] [31] [32] and, in a recent study [28] , prevent the atrophy of Peyer's patches and dysfunction of M cell in rabbits receiving long-term parenteral nutrition. These studies suggest GRP agonists may have a potential therapeutic role in diseases causing this type of injury. Numerous studies in rodents provide evidence that GRP/BB 2 -receptor activation is important for memory, as well as a number of social behaviors (learning, grooming, stereotypy) [22 ,33] . These results were supported by a recent study [34] in which the administration of BB 2 -receptor antagonists in neonatal rats resulted in marked impairment of memory and social interaction. These changes have led one group [22 ] to propose that the BB 2 -receptor should be considered a therapeutic target in a subset of human CNS diseases, especially those involving memory, learning and fear. In a recent study [39 ] using BB 1 -receptor knockout mice, the importance of NMB as a physiological regulator of pituitary-thyroid axis function and gene expression was confirmed. In this study [39 ] , BB 1 -receptor activation was found to be important for thyrotroph gene regulation and function, with its activation leading to a state in which TSH release is facilitated, especially in response to TRH. In two recent studies [40 ,41] in rats using various bombesin receptor antagonists, evidence was provide that BB 1 -receptor activation affects both anxiety and fear responses, while the BB 2 -receptor affected the fear response, and it was proposed that antagonists to the BB 1 -receptor as well as the BB 2 -receptor might represent a novel class of anxiolytic agents.
BB 3 receptors: recent advances
As there are no specific antagonists to this receptor, the synthetic agonist, [D-Tyr 6 , b-Ala 11 , Phe 13 , Nle 14 ] bombesin 6-14, is a nonselective agonist for this receptor and the natural ligand is unknown, the clues to its possible role in physiological and pathological processes have come from studies of BB 3 -receptor knockout mice or from proposals from localization studies of the receptor [3 ] . The initial study of BB 3 -receptor knockout mice [42] reported the mice had mild obesity, hypertension and impairment in glucose metabolism, which were associated with increased feeding behavior and increased leptin levels. A subsequent study showed these knockout mice have a 2.3-fold increase in insulin levels and the impaired glucose metabolism is mainly due to impaired GLUT4 translocation in adipocytes [43] . Another study demonstrated increased levels of the melanin-concentrating hormone (MCH) receptor and prepro-MCH in the hypothalamus of BB 3 -receptor knockout mice, and it was proposed that this situation may trigger the hyperphagia. Other studies demonstrated these animals have altered behaviours, including modulating anxiety [3 ,44] .
Recent studies demonstrate that BB 3 -receptor-containing cells are expressed in developing and fetal lungs, and the expression is increased in response to injury, such as after inhalation of ozone, and this results in proliferation of bronchial epithelial cells [3 , 45, 46] . A recent study demonstrates [46] that ozone stimulates AP-2 alpha and PPARalpha to increase the activity of the BB 3 -receptor gene promoter, leading to increased BB 3 -receptor expression. An additional insight into a possible role for the BB 3 -receptor in the gastrointestinal tract came from a recent receptor localization study [6] , in which the BB 3 -receptor was found in highest densities in myenteric/submucosal ganglia and in the c-kit interstitial cells of Cajal. The authors proposed that it may be involved in regulating motility, because of the known pacemaker function of these cells.
BB receptors: recent advances, satiety
Numerous studies have demonstrated that the three bombesin receptor subtypes are involved in satiety [3 ,47] . Evidence from some studies suggests that activation of these receptors can have direct and indirect effects on satiety cascades, because bombesin can block the orexigenic effect of ghrelin [47, 48] .
A recent study [36 ] demonstrates that the BB 2 -receptor's satiety effects are mediated through different peripheral neural pathways than the BB 1 -receptor-mediated satiety. This conclusion was reached because only the BB 1 -receptor's satiety effects were inhibited by capsaicin, suggesting an involvement of primary sensory afferent pathways only in the BB 1 -receptor pathway [36 ] . A recent study [49] demonstrates that NMB is expressed in both human and rodent adipose tissue and is regulated by changes in energy balance. It is proposed [36 ] that because of NMB's known anorectic effect centrally, this association may form a part of a new adipose tissuehypothalamic axis regulating food intake. The importance of the BB 3 -receptor in satiety was discussed earlier in the section dealing with this receptor.
BB receptors: recent advances, tumor growth/ differentiation
Activation of each of the bombesin receptor classes can have growth effects in both normal and neoplastic tissues [3 ,18 ,19 ] . Furthermore, bombesin receptors are one of the most frequent receptor classes that are overexpressed/ectopically expressed by human cancers [8,18 ,19 ,50,51] . Both NMB and GRP have been shown to have autocrine growth effects in a number of human tumors, including tumors of the lung, head and neck, CNS, pancreas, prostate and colon [3 ,18 ,19 ]. In addition, activation of BB 2 -receptors can have proangiogenic effects [3 ,52] .
Recent studies provide evidence that activation of each of the bombesin receptor family can have growthpromoting effects in some tumors [3 ,18 ,19 ]. Recent studies demonstrate in some tumors that the growth effects of BB 2 -receptor activation are mediated by transactivation of the EGF receptor, which is dependent on Src-mediated cleavage and release of TGF-a and amphiregulin with stimulation of the PI3K pathway [3 ,53,54 ,55] . Detailed studies, however, of the effect of ectopic expression of the BB 2 -receptor and GRP by human colon cancers provide evidence in this tumor that their primary effect is to function as a morphogen or differentiating factor rather than as a mitogen or growthstimulating factor [56] . This morphogenic effect is mediated by activation of p125 FAK , which enhances cell attachment and is caused by upregulation of ICAM-1 [57, 58 ].
Studies of the growth effects of bombesin-related peptides on human tumors using bombesin receptor inhibitors either alone or with other agents [3 ,55,59-62] demonstrate prominent inhibition of tumor growth in many cases, resulting in the proposal that these compounds either alone or with other antitumor treatment could be used as a possible novel therapeutic approach [3 ,59,63] . Recently, a phase I trial of a BB 2 -receptor antagonist, RC-3095 was reported in patients with advanced solid tumors [64 ] . No toxicity was seen and no objective responses were seen; however, the targeted plasma level was not achieved even with dose escalation, and it was proposed that newer drug-delivery systems would need to be developed to fully evaluate this approach.
BB receptors: recent advances, tumor imaging and receptor-targeted cytotoxicity of tumors
The overexpression/ectopic expression of bombesin receptors by human tumors is being investigated to use in their localization and to target cytotoxic agents [3 ,18 ,63,65,66 ]. This approach is now widely used clinically with many neuroendocrine tumors using technetium) GRP analogues with enhanced stability that bind with high affinity to BB 2 -receptors are reported, as well as the ability to image various human tumors in vivo using gamma detectors or PET imaging [10 ,69-77] . In some preliminary studies in humans, tumors were imaged in the majority of patients and, in some cases, tumors were detected using radiolabeled bombesin analogues that were not seen on other commonly used imaging modalities [75, [78] [79] [80] . At present, no study has established the value of imaging using radiolabeled bombesin analogues.
A number of bombesin analogues coupled to radiolabeled compounds ( 177 lutetium) [69, 70, 81, 82 ] , as well as to cytotoxic agents (camptothecin -a topoisomerase inhibitor, doxorubicin analogues, paclitaxel) [65,66 ,83-85,86 ,87,88], have been described that retain high affinity for bombesin receptors. They are internalized by bombesin-receptor-bearing tissues and are being evaluated for the possibility of delivering bombesin-receptormediated tumoral cytotoxicity. Many of these compounds have been shown to cause tumor cytotoxicity in animal studies, and one study has provided evidence that it is due to specific interaction with the BB 2 -receptors overexpressed on the tumor [66 ] . At present, it is unclear whether this approach will be effective in vivo in human tumors whether alone or in combination with other antitumor treatments.
Conclusion
Increasing evidence suggests that members of the mammalian bombesin-receptor family (BB 1 , BB 2 , BB 3 ) are involved in a large number of CNS and peripheral responses, both physiologically and in disease states. Especially important are their roles in various CNS processes and behaviors, lung diseases, mediation of pruritus and in regulation of tumor growth. An increasing understanding of the exact role of these receptors in each of these areas has an increasing potential for the development of novel therapies.
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